NCT00045305View on ClinicalTrials.gov

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 24, 2006

Primary Completion Date

February 28, 2014

Study Completion Date

September 30, 2014

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
DRUG

Cyclosporine

Immunosuppressant

DRUG

Methotrexate

Antimetabolite

DRUG

Photopheresis

Psoralens

DRUG

Mycofenolate mofetil

an antibiotic with immunosuppressamt properties isolated from Penicillium spp

DRUG

Pentostatin

Purine analogue

PROCEDURE

allogeneic bone marrow

Unmanipulated allogeneic bone marrow

PROCEDURE

peripheral blood stem cell

G-CSF mobilized peripheral blood stem cell

RADIATION

Total body irradiation

a total of 600 cGy given in 3 200 cGy fractionated doses

Trial Locations (6)

32224

Mayo Clinic - Jacksonville, Jacksonville

45236

Jewish Hospital Cancer Center, Cincinnati

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale

02111

Tufts-NEMC Cancer Center, Boston

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT00045305 - Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter